Navigation Links
Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
Date:1/14/2010

CHICAGO, Jan. 14 /PRNewswire/ -- Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays.  The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.  These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.

"We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research," said Professor Judith Luborsky, Ph.D., Associate Dean for Research, College of Health Sciences, Director, Laboratory for Ovarian Cancer Research and Director, Rush Proteomics & Biomarkers Core Research Facility at Rush University Medical Center.  "The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements.  In fact, we have included Sword technology in several grants we are currently applying for."

"We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs," said Dave Dingott, founder and CEO of Sword Diagnostics.  "The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective."

About Sword Diagnostics

Sword Diagnostic's mission is to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test as well as allowing researchers to monitor new markers that are not readily detectable with current technology.  This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer's disease.  Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.  The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry.  The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.  

www.sworddiagnostics.com

SOURCE Sword Diagnostics Inc.

RELATED LINKS
http://www.sworddiagnostics.com

'/>"/>

SOURCE Sword Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
2. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
3. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
4. Fujirebio Diagnostics Named Life Sciences Company of the Year
5. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
6. Roche Diagnostics Opens State-of-the-Art Training Center in California
7. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
8. Reportlinker Adds Molecular Diagnostics - A World Market Review
9. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
10. Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective
11. VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Spotlight Innovation ... Caretta Therapeutics plans, in the second quarter of ... topical roll-on intended to provide relief from chronic ... steroidal analgesics. It was developed under a licensing ... commercialize products derived from snake venom. Additionally, Caretta ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... from 6% to 10%, South East Asia,s pharma industry is ... the industry by fostering the regional discourse - Sign up today ! ... ASEAN -- India strategic sourcing Forum ... business matchmaking program Roadshows ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... , The company, owned and operated by Ed Stroup, was created to ... price with the highest level of customer service. Healthful Balance products can be ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... Louisiana (PRWEB) , ... January 17, 2017 , ... ... Senior Medical Center joined the Peoples Health network on Dec. 1, 2016. ... beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our provider ...
Breaking Medicine News(10 mins):